Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials -

Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials
Information type: Randomised controlled trials
Source: The Lancet Oncology
Specialities: Cancers | Respiratory disorders
Summary
In both RCTs (total n=979), over a period of 12 weeks, lean body mass increased in patients receiving anamorelin (median increase 0.99kg) v placebo (p<0.0001), although no statistically significant difference in strength of handgrip was noted in either study.
UKMi comment
Anamorelin is a ghrelin-receptor agonist. A marketing authorisation application for cancer cachexia in patients with advanced non-small-cell lung cancer is currently under review by the European Medicines Agency, which if approved, may result in the launch of anamorelin in the fourth quarter of 2016.
Related links: